Azacitidine and venetoclax with or without quizartinib for older or unfit AML patients
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests if adding quizartinib to the standard combination of azacitidine and venetoclax improves outcomes for older adults or those with health conditions who cannot have intensive chemotherapy for acute myeloid leukemia (AML). It may help patients with certain genetic changes in the FLT3 or NPM1 genes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed AML that hasn't been treated yet.
- You cannot get standard intensive chemotherapy because of your age (75 or older) or because of other health problems (like heart, lung, or kidney issues).
- You haven't had prior treatment with azacitidine, venetoclax, or quizartinib.
- Your white blood cell count is no higher than 25,000 before starting.
- You don't have active leukemia in your brain or spinal fluid.
- You agree to follow study rules about pregnancy prevention.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines three drugs to treat certain types of leukemia or a related blood condition. It may be an option for people who cannot have standard intensive chemo, or for those whose disease has come back.
This trial tests a combination of medicines (venetoclax and a hypomethylating agent) for people with acute myeloid leukemia (AML) who have a FLT3 mutation. It may be an option for older adults or those who cannot tolerate intensive chemotherapy.
This Phase 2 study tests whether the combination of azacitidine and venetoclax can help people with acute myeloid leukemia (AML) who can’t handle standard intensive chemotherapy, including some relapsed or refractory cases. It also involves extra optional-style lab testing on your leukemia (bio-banking and “-omics” profiling) to learn which drug sensitivities may matter.
This Phase 2 trial tests a combination of venetoclax, cladribine, low-dose cytarabine, and azacitidine in people with untreated acute myeloid leukemia (AML). It may help shrink the leukemia and improve blood counts by trying a stronger, multi-drug approach.
This early-phase trial tests whether azacitidine (CC-486) plus venetoclax can help people with acute myeloid leukemia (AML) that is not APL. It’s designed to find safe dosing and see how well the combination works for newly diagnosed or relapsed/refractory AML.
This trial tests a new drug combination (bleximenib, venetoclax, and azacitidine) for people with a specific genetic type of AML who cannot receive strong chemotherapy. The goal is to see if this combination is safer and more effective.
Hear when a new Acute Myeloid Leukemia, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.